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The mechanisms by which melanoma and other can-
cer cells evade anti-tumor immunity remain incom-
pletely understood. Here, we show that the growth of
tumors formed by mutant BrafV600E mouse melanoma
cells in an immunocompetent host requires their pro-
duction of prostaglandin E2, which suppresses immu-
nity and fuels tumor-promoting inflammation. Genetic
ablation of cyclooxygenases (COX) or prostaglandin E
synthases in BrafV600E mouse melanoma cells, as well
as inNrasG12Dmelanomaor inbreastorcolorectal can-
cer cells, renders them susceptible to immune control
and provokes a shift in the tumor inflammatory profile
toward classic anti-cancer immune pathways. This
mouse COX-dependent inflammatory signature is
remarkablyconserved inhumancutaneousmelanoma
biopsies, arguing for COX activity as a driver of im-
mune suppression across species. Pre-clinical data
demonstrate that inhibition of COX synergizes with
anti-PD-1 blockade in inducing eradication of tumors,
implying that COX inhibitors could be useful adjuvants
for immune-based therapies in cancer patients.
INTRODUCTION
Inflammation has emerged as a major factor promoting cancer
development (Coussens et al., 2013; Grivennikov et al., 2010;
Mantovani et al., 2008; Rakoff-Nahoum and Medzhitov, 2009).
Tumor-promoting inflammation is characterized by the presence
of sub-types of neutrophils, macrophages, dendritic cells (DCs),
and T lymphocytes that support cancer progression (Balkwill
et al., 2005; Coussens et al., 2013; Mantovani et al., 2008). Medi-
ators secreted by these cells that directly or indirectly promote
cancer cell growth include cytokines, chemokines, and growth
factors, such as VEGF-A, CSFs, IL-1, IL-6, IL-8, or CXCL1 (Balk-
will et al., 2005; Coussens et al., 2013). Yet inflammation can alsoChave cancer-inhibitory effects (Coussens et al., 2013; Mantovani
et al., 2008), in part by favoring immune attack (Vesely et al.,
2011). Indeed, in most mouse and human cancers, the presence
of immune cells, such as cytotoxic T cells and DCs (in particular,
the Batf3-dependent CD103+ sub-type), or of inflammatory me-
diators, such as type I interferons (IFNs), IFN-g, and IL-12, is
associated with good prognosis (Fridman et al., 2012; Gajewski
et al., 2013; Vesely et al., 2011). Notably, several ‘‘immunecheck-
point blockade’’ therapies aimed at unleashing the anti-cancer
potential of tumor-specific T cells have recently shown great
promise (Page et al., 2014; Sharma and Allison, 2015). These ob-
servations suggest that cancer cells do not pass unnoticed by the
immune system but actively evade anti-tumor immunity.
In line with the above, tumors arising in immunosufficient hosts
are commonly poorly immunogenic as a consequence of immu-
noediting (Schreiber et al., 2011). Reduced tumor immunoge-
nicity can be a ‘‘recessive’’ consequence of downregulation of
antigen-presentingMHCmolecules or loss of antigens that serve
as targets for T cell-mediated control (DuPage et al., 2012; Mat-
sushita et al., 2012). Loss of immunogenicity can also be due
to blockade of T cell access to tumor cell targets, recruitment
of suppressive cells, and/or production of immunosuppressive
factors (Joyce and Fearon, 2015). The latter can act in part by
dampening production of type I interferons, IL-12, and other fac-
tors that are required for priming or restimulating anti-tumor
T cells and for sustaining T cell-independent anti-tumor immunity
(Dunn et al., 2005; Vesely et al., 2011). Unlike recessive mecha-
nisms of immunoediting, immunosuppressive factors act in a
dominant fashion and therefore offer a unique opportunity for im-
mune therapy intervention so long as the antigenic determinants
for tumor rejection have not been lost.
Inflammatory mediators can be produced by the stroma, by
tumor-infiltrating leukocytes, or directly by the cancer cells
themselves. Prominent among tumor-sustaining mediators is
prostaglandin E2 (PGE2), a prostanoid lipid associated with
enhancement of cancer cell survival, growth, migration, inva-
sion, angiogenesis, and immunosuppression (Wang and Dubois,
2010). Cyclooxygenase (COX)-1 and 2, enzymes critical for the
production of PGE2, are often overexpressed in colorectal,ell 162, 1257–1270, September 10, 2015 ª2015 The Authors 1257
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Figure 1. COX-1- and COX-2-Dependent Tumor-Derived Prostanoids Modulate Myeloid Cells
(A) Growth of BrafV600E cells following implantation into WT and Rag1/mice. Data are presented as average tumor diameters ± SEM and are representative of
three independent experiments with three to fivemice per group. Tumor growth profiles were compared using two-way ANOVA. *p < 0.05, **p < 0.01, ***p < 0.001.
(B and C) BMMCs were cultured in the presence or absence of CM from BrafV600E cells with or without LPS (100 ng/ml). The concentration of TNF, IL-12/23 p40,
and MIP1a (B) or IL-6, CXCL1, and G-CSF (C) in supernatants was determined after overnight culture.
(D) BrafV600E cells unmodified (parental), control, stably expressing a Ptgs2-specific targeting shRNA construct, Ptgs2/, or Ptgs1/Ptgs2/ were cultured to
confluency, and the concentration of PGE2 in the supernatant was determined by ELISA.
(E) Immunoblot of COX-2 and COX-1 in parental BrafV600E cells and three independent control, Ptgs2/, or Ptgs1/Ptgs2/ clones generated by CRISPR/Cas9-
mediated genome engineering using distinct sets of sgRNAs targeting different regions of the Ptgs1 and Ptgs2 loci. p97 served as a loading control.
(legend continued on next page)
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breast, stomach, lung, and pancreatic cancers (Dannenberg and
Subbaramaiah, 2003; Wang and Dubois, 2010). Here, we identify
tumor-derivedCOXactivity in amousemelanomadriven, as inhu-
man, by an oncogenic mutation in Braf, as the key suppressor of
type I IFN- and T cell-mediated tumor elimination and the inducer
of an inflammatory signature typically associatedwith cancer pro-
gression. COX-dependent immune evasion was also critical for
tumor growth in other melanoma, colorectal, and breast cancer
models. Notably, tumor immune escape could be reversed by a
combination of immune checkpoint blockade and administration
of COX inhibitors, suggesting that the latter may constitute useful
additions to the arsenal of anti-cancer immunotherapies.
RESULTS
BrafV600E Melanoma Cell Supernatants Have
Immunomodulatory Effects on Myeloid Cells
In order to identify immune evasion mechanisms operative in
melanoma, we used a transplantable tumor cell line established
from a Braf+/LSL-V600E;Tyr::CreERT2+/o;p16INK4a/mouse (Dho-
men et al., 2009) (henceforth, BrafV600E cells). We reasoned that
such cells, isolated from a genetically engineered cancer-prone
mouse bearing an intact immune system, are likely to possess
key attributes that allow them to escape immune control in the
original host. Indeed, underscoring their poor immunogenicity,
BrafV600E melanoma cells formed progressively growing tumors
upon implantation into wild-type (WT) mice, and this was only
marginally enhanced in T- and B-cell-deficient Rag1/ mice
(Figure 1A). We tested whether the poor immunogenicity of
BrafV600E cells could result from compromised or subverted acti-
vation of antigen-presenting cells, including dendritic cells (DCs)
and monocyte-derived cells. We cultured mouse bone marrow-
derived mononuclear cells (BMMCs), a mixed population of DCs
and monocyte-derived macrophages (Helft et al., 2015), with
conditioned medium (CM) from BrafV600E cells in the presence
or absence of a strong innate immune stimulus, lipopolysaccha-
ride (LPS). Remarkably, LPS-induced production of TNF, IL-12/
23p40, and MIP1a by BMMCs was strongly inhibited by CM
from BrafV600E cells (Figure 1B). Moreover, addition of CM alone
induced a distinct set of proinflammatory mediators, including
IL-6, CXCL1, and G-CSF (Figure 1C). The latter, as well as IL-
1b, IL-10, and RANTES, were also induced by LPS, but CM,
if anything, enhanced their accumulation (Figure S1A). Thus,
tumor-derived secreted factors subvert the normal pattern of
myeloid cell-driven inflammation.
Cyclooxygenase-Dependent Prostanoids Account for
the Immunomodulatory Effects of BrafV600E Tumors on
Myeloid Cells
Neither heat inactivation (to denature proteins) nor benzonase
treatment (to degrade nucleic acids) impacted the ability of tu-(F) BMMCs were cultured in the presence of increasing amounts of synthetic PGE
LPS) in the supernatant was determined after overnight culture.
(G) BMMCs were cultured as in (B) or (C) in presence of CM from the indicated Br
expressed relative to the concentration of TNF in the supernatant of BMMCs cultu
6 is expressed relative to the concentration of IL-6 in the supernatant of BMMCs c
See also Figures S1, S2, S3, and S4.
Cmor CM to promote IL-6 production or inhibit LPS-dependent in-
duction of TNF by BMMCs (Figure S1B). We therefore investi-
gated whether the immunomodulatory factor might be a lipid.
The ability to inhibit IL-12 p40 production was reminiscent of
the effects of the prostanoid PGE2 (Kalinski, 2012), which we
found in high amounts in CM fromBrafV600E melanoma cells (Fig-
ure 1D). These cells also expressed cyclooxygenase (COX)-1
and -2, two enzymes critical for prostanoid synthesis (Figure 1E).
Treatment with a Braf or a MEK inhibitor led to reduced COX-2
protein and PGE2 secretion, indicating that COX-2 expression
in BrafV600E cells was dependent on active RAF/MEK signaling
(Figure S2).
Addition of synthetic PGE2 to BMMCs mimicked the effect of
CM (Figure 1F). To assess the importance of COX-2-derived
prostanoids, we targeted the Ptgs2 gene (encoding COX-2) in
BrafV600E melanoma cells with several small hairpin RNAs
(shRNAs). Although COX-2 expression was clearly diminished
(Figure S3), the concentration of PGE2 in CM from these cells
was only modestly reduced and the modulatory effect of CM
on BMMCs was unchanged (Figures 1D and 1G). As residual
COX-2 expression could account for these observations, we
resorted to CRISPR/Cas9 technology to generate Ptgs2/
(COX-2-deficient) BrafV600E melanoma cells (Figure 1E). Produc-
tion of PGE2 by Ptgs2
/ CRISPR-targeted clones was greatly
decreased (Figure 1D), and their CM was no longer able to
inhibit LPS-mediated TNF production or to induce IL-6 secretion
by BMMCs (Figure 1G). These data demonstrate that COX-2
expression largely accounts for the myeloid cell modulatory
properties of CM from BrafV600E melanoma cells. Of note, in
agreement with previous reports (Dannenberg and Subbara-
maiah, 2003), we found PGE2 in CM from many, but not all,
mouse cancer cell lines, including 4T1 breast cells, CT26
colorectal cells, a line derived from a NrasG12D-driven mela-
noma-bearing mouse (Pedersen et al., 2013), and a methyl-
cholanthrene-induced fibrosarcoma (Matsushita et al., 2012)
(Figure S4).
COX Activity in BrafV600E Cells Shifts the Inflammatory
Profile at the Tumor Site
To test the effect of tumor-derived prostanoids in vivo, we inoc-
ulated WT mice with parental or Ptgs2/ BrafV600E cells and as-
sessed the expression of an array of inflammatory and immune
mediators in whole-tumor biopsies of comparable size (Fig-
ure 2A), containing immune-infiltrating cells, at 4 days post-im-
plantation. In agreement with the effects seen in vitro, loss of
COX-2 expression by tumor cells led to a significant decrease
in expression of IL-6 or CXCL1 in vivo (Figures 2B and 2C). In
contrast, several mRNAs encoding known anti-tumor immune
mediators or reflective of anti-tumor type I immunity, including
IFN-g, T-bet, CXCL10, and IL-12 (Vesely et al., 2011), weremark-
edly increased in Ptgs2/ melanomas (Figures 2B and 2D).2 plus or minus LPS (100 ng/ml). The concentration of TNF (+LPS) and IL-6 (no
afV600E melanoma cell lines. The concentration of TNF after overnight culture is
red in presence of LPS without any CM (% of medium). The concentration of IL-
ultured with CM from parental BrafV600E cells (% of parental). nd, not detected.
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Figure 2. Genetic Ablation of COX in BrafV600E Cells Shifts the Tumor Inflammatory Profile
(A–E)WTmice were inoculated with 106 control, Ptgs2/, or Ptgs1/Ptgs2/BrafV600E cells. 4 days later, the expression of an array of immune-associated genes
was determined by qPCR in whole-tumor homogenates.
(A) Tumor weight at the time of harvest is shown.
(B) Heatmaps for a selected list of genes show log2 DCT values normalized to hprt of two biological replicates for each value. The genes are ordered from highest
to lowest by fold change in control relative to Ptgs2/ or Ptgs1/Ptgs2/ samples.
(C and D) Relative expression of each gene normalized to hprt.
(E) Concentration of PGE2 in lysates from 10
5 total tumor cells. Each dot represents one independent tumor.
See also Figure S5.Likewise, mRNA levels of Ifit1 and Ifit2, two type I IFN-stimulated
genes (ISGs), were also elevated in Ptgs2/ tumors (Figure 2D),
indicative of enhanced type I interferon (IFN-a/b) signaling, which
is central to immune-mediated tumor control (Gajewski et al.,
2013; Vesely et al., 2011). We failed to detect a reduction in
the expression of type 2 cytokines, such as IL-4, IL-5, or IL-13,
or markers associated with M2 macrophage polarization, such
as iNOS, arginase I, Gas-3, or E-cadherin (Figure S5; data
not shown), despite the fact that they have been reported to1260 Cell 162, 1257–1270, September 10, 2015 ª2015 The Authorsbe induced by prostanoids within tumors (Wang and Dubois,
2010). Also, we did not detect decreased expression of IL-10
(Figure 2B), an anti-inflammatory cytokine that has been sug-
gested to mediate many of the immunosuppressive effects of
COX-2 (Kalinski, 2012).
Even though COX-2 activity accounted for more than 90% of
PGE2 production by Braf
V600E cells, we still detected low levels
of PGE2 and some degree of BMMC modulatory activity in
supernatants from Ptgs2/ cells, particularly from clones that
stochastically displayed higher COX-1 expression (Figures 1D
and 1G; data not shown). To fully eliminate COX activity and
avoid potential in vivo selection for cells that compensate
for COX-2 deficiency by upregulating COX-1, we generated
COX-1 and COX-2 doubly deficient BrafV600E cells (Ptgs1/
Ptgs2/ cells; Figure 1E). These cells fully lacked the ability to
produce PGE2 and did not modulate the activity of BMMCs
in vitro (Figures 1D and 1G). Tumors formed by Ptgs1/Ptgs2/
cells displayed markedly reduced global PGE2 levels, indicating
a dominant role for tumor-derived over stroma-derived PGE2
in vivo (Figure 2E). Importantly, as for Ptgs2/ singly deficient
cells, a clear shift in the inflammatory profile toward increased
expression of anti-tumor immune mediators was seen in tumors
formed by Ptgs1/Ptgs2/ doubly deficient cells (Figure 2B). We
conclude that BrafV600Emelanoma-derived prostanoids drive the
expression of multiple tumor-promoting cytokines and growth
factors in the local tumor microenvironment, while preventing
type I immunity and other anti-tumor immune effector pathways,
including those controlled by type I IFNs.
COX Expression in BrafV600E Cells Prevents CD103+ DC
Accumulation and Activation in Tumors
DCs, especially the Batf3-dependent sub-family characterized
by CD8a and/or CD103 expression, are essential for anti-cancer
immune responses (Diamond et al., 2011; Fuertes et al., 2011;
Hildner et al., 2008). We therefore assessed the impact of
tumor-specific COX ablation on the prevalence and activation
status of DCs at the tumor site, focusing on the CD103+ subset.
Despite being only a minority of DCs, CD103+ DCs were selec-
tively absent from COX-competent tumors (Figure 3A). More-
over, the fraction of intratumoral CD103+ DCs producing IL-12
p40 was higher in COX-deficient tumors (Figure 3B). Finally,
CD103+ DCs, as well as CD103 CD11b+ DCs, displayed higher
levels of costimulatory molecules in tumors formed by Ptgs1/
Ptgs2/ cells (Figure 3B). Thus, tumor-derived prostanoids
impair accumulation of Batf3-dependent CD103+ DCs within
tumors and suppress their activation, including IL-12-producing
activity.
Genetic Ablation of COX in BrafV600E Cells Permits
Tumor Control by Innate and Adaptive Immune
Mechanisms
Given the COX-dependent phenotypes described above, we
sought to establish the contribution of COX to the ability of
BrafV600E melanoma cells to grow in immunocompetent mice.
Notably, Ptgs1/Ptgs2/ cells formed spontaneously regressing
tumors in WT mice in contrast to a COX-sufficient control clone
which, despite having undergone the CRISPR/Cas9-mediated
targeting procedure, retained COX-1 and COX-2 expression
(Figure 1E) and grew similarly to the parental cells (Figure 4A).
Importantly, Ptgs1/Ptgs2/ tumors were able to grow in
Rag1/, Tap1/, and Batf3/ hosts (Figures 4A and 4B), indi-
cating that prostanoid deficiency did not impair tumor formation
in a cell-intrinsic fashion but rather acted to prevent CD8a+/
CD103+ DC-dependent rejection mediated by CD8+ T lympho-
cytes. Similar results were obtained using two other independent
Ptgs1/Ptgs2/ clones generated using a different set of single-
guide RNAs (sgRNAs) (Figures 1E and S6A). Thus, COX activity isCa key driver of adaptive immune escape by BrafV600E melanoma
cells.
Tumors formed by Ptgs1/Ptgs2/BrafV600E cells were notice-
ably smaller than their COX-sufficient counterparts even before
adaptive immunity is expected to impact on tumor size (Fig-
ure 4A). As none of the Ptgs1/Ptgs2/ cell lines showed an
obvious proliferative impairment in vitro (Figure S6B), we investi-
gated whether a T and B lymphocyte-independent innate im-
mune response was responsible. Given the COX-dependent
inhibition of ISGs observed in the tumor microenvironment (see
above), we examined the role of host type I IFN signaling in initial
tumor growth control. We found that Ptgs1/Ptgs2/ tumors
grew considerably faster in Ifnar1/ mice than in WT animals
during the first 8 to 10 days post-inoculation, indistinguishably
from tumors formed by parental COX-expressing BrafV600E cells
(Figure 4C). Of note, the growth of the latter was unaffected by
IFNAR deficiency, consistent with the fact that they do not
display an IFN signature (Figures 2B and 2D). These data indi-
cate that an early type I IFN-dependent innate immune response
restricts the growth of Ptgs1/Ptgs2/ cells.
Finally, we assessed the development of immunity following
challenge with Ptgs1/Ptgs2/ tumors. Most mice that rejected
Ptgs1/Ptgs2/ cells were resistant to a subsequent challenge
with unmodified parental BrafV600E melanoma cells (Figure 4D),
implying the development of immunity to shared target antigens
and excluding a scenario of cancer immune privilege driven
locally by tumor-derived prostanoids.
An Essential Role for PGE2 in Braf
V600E-Melanoma
Immune Escape
COX-1 and COX-2 are essential for the production of multiple
prostanoids, and COX deficiency can shunt arachidonic acid
into different metabolic pathways (Ricciotti and FitzGerald,
2011). To evaluate the specific contribution of PGE2, we gener-
ated BrafV600E melanoma cells genetically deficient in micro-
somal prostaglandin E synthase (mPGES)-1 and -2 (referred to
as Pges/ cells), two of the enzymes specifically required for
the synthesis of PGE2, but not other prostanoids. PGES-defi-
cient melanoma cells phenocopied COX-deficient ones in that
their CM lacked BMMC immunomodulatory activity (Figure 4E),
and they were spontaneously rejected in immune competent re-
cipients but grew progressively in T- and B-cell-deficient hosts
(Figure 4F). Thus, these data indicate amajor and non-redundant
role for PGE2 among prostanoids in the ability of Braf
V600E mela-
noma cells to avoid immune destruction.
COX-Dependent Immune Escape Is a Feature of
Different Mouse Cancer Cells
To extend our findings, we examined the ability of COX to facili-
tate immune escape of other mouse cancers. A melanoma
cell line driven by expression of NrasG12D in melanocytes (Peder-
sen et al., 2013) also produced PGE2 and formed tumors that
were practically identical in Rag-sufficient and Rag-deficient
mice (Figure 4G). In contrast, NrasG12D melanoma cells rendered
genetically deficient inCOX-2were spontaneously rejected inWT
mice but grew like parental COX-2-competent tumors inRag1/
hosts (Figure 4G). Mice that rejected Ptgs2/ tumors subse-
quently rejected parental COX-competent NrasG12D melanomaell 162, 1257–1270, September 10, 2015 ª2015 The Authors 1261
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Figure 3. Tumor-Derived Prostanoids Prevent CD103+ DC Accumulation and Activation
(A and B) WT mice were inoculated with 106 parental or Ptgs1/Ptgs2/ BrafV600E cells and tumor-infiltrating DCs were analyzed 4 days later. (A) Left: repre-
sentative fluorescence-activated cell sorting (FACS) plots for CD103 versus CD11b within a CD11c+ MHCII+ DC gate. Right: percentage and number (#) of
CD103+ CD11c+ MHCII+ or CD11c+ MHCII+ cells. (B) Upper: representative FACS plots for CD11c versus IL-12p40 or CD86 versus CD40 within a CD103+ or
CD11b+ CD11c+ MHCII+ gate. Lower: percentage of IL-12p40+ or CD86+ CD40+ within CD103+ or CD11b+ CD11c+ MHCII+ cells. Each symbol in (A) and (B)
represents an independent tumor. Samples were compared using two-tailed Student’s t test. *p < 0.05, **p < 0.01, ***p < 0.001.cells (Figure 4H), indicating the development of immunological
memory and underscoring the presence of cryptic rejection anti-
gens in parental NrasG12D melanoma cells. In contrast to experi-
ments with BrafV600E cells, we did not find an obvious component
of COX-dependent early innate immune control of NrasG12D cells
via type I IFN (data not shown).1262 Cell 162, 1257–1270, September 10, 2015 ª2015 The AuthorsTo assess cancers other than melanoma and use mouse
strains other than C57BL/6, we chose CT26 colorectal and
4T1 breast cancer cell lines that grow in BALB/c mice and
also display constitutively active RAS/RAF/MEK/ERK signaling
(Castle et al., 2014; Phan et al., 2013) and produce PGE2 (Figures
5A and S4). Like the melanoma lines, these cancer cells exerted
immunomodulatory effects on BMMCs in vitro and grew identi-
cally in WT and T-cell-deficient nude mice (Figures 5A and 5B).
In either case, genetic ablation of COX rendered the cells unable
to produce PGE2, abrogated their immunomodulatory effects on
BMMCs, and allowed a marked degree of T-cell-dependent
tumor growth control (Figures 5A and 5B). As for BrafV600E cells,
COX-deficiency was associated with a shift in the inflammatory
profile at the tumor site, with reduced expression of tumor pro-
moting factors, such as Il6 or Il1b and increased levels of medi-
ators associated with anti-tumor immune pathways (Figure 5C).
Finally, mice that fully rejected COX-deficient CT26 or 4T1
tumors were immune to subsequent challenge with the res-
pective COX-competent parental lines (data not shown). We
conclude that prostanoid-dependent subversion of the inflam-
matory response and escape from anti-cancer immunity is a
general feature of COX-expressing tumors.
COX Inhibitors Enhance the Efficacy of Immunotherapy
with an Anti-PD-1 Blocking Antibody
Aspirin blocks both COX-1 and COX-2 and can be administered
to mice in drinking water. However, this had no effect on the pro-
gression of implantedCOX-competent BrafV600Emelanoma cells
(Figures 6A–6C), perhaps because of incomplete inhibition of
COX activity. However, even a modest degree of COX inhibition
might help enhance the efficacy of immunotherapies, including
those based on immune checkpoint blockade. Consistent with
that notion, aspirin in the drinking water, in combination with
treatment with anti-PD-1 monoclonal antibody, promoted much
more rapid tumor regression and eradication of BrafV600E mela-
noma cells than anti-PD-1 alone (Figures 6A and 6B). The potent
synergy of the aspirin/anti-PD-1 combination was fully depen-
dent on adaptive immunity as it was lost in Rag1/ mice (Fig-
ure 6B). It was also manifest in experiments using a larger
inoculum of tumor cells, in which anti-PD-1 blockade alone had
no effect (Figure 6C). Mice that fully eradicated COX-sufficient
tumors upon treatment with aspirin + anti-PD-1 were immune
to a subsequent challenge in the absence of further treatment
(Figure 6D). Administration of celecoxib, a COX-2-specific inhib-
itor, also significantly synergized with anti-PD-1 treatment (Fig-
ure 6E), albeit to a lesser degree than aspirin, possibly due to
suboptimal COX-2 inhibition and/or a potential contribution
of COX-1-derived PGE2. Finally, we addressed whether the syn-
ergy of the combination could be observed with tumors besides
melanoma. Notably, treatment of mice bearing CT26 colorectal
tumors with aspirin and anti-PD-1-induced tumor growth control
and rapid and complete shrinkage in 30% of mice, whereas
monotherapy showed little efficacy (Figure 6F). These experi-
ments suggest that COX inhibitors could be useful additions
to immune checkpoint blockade or conventional treatment of
cancer patients so long as prostanoids also constitute a means
of tumor immune escape in humans.
The COX-Dependent Inflammatory Signature Is
Conserved in Human Cutaneous Melanoma Biopsies
To evaluate the latter, we asked whether evidence for COX-
dependent immune modulation can be found in human mela-
nomas. We correlated PTGS2 (encoding COX-2) mRNA expres-
sion levels in human melanoma biopsies containing tumor, asCwell as stromal and infiltrating, cells with levels of mRNAs encod-
ing various immune mediators, including those that we found to
be controlled by COX-2 in the mouse models. Strikingly, mRNA
expression levels for IL-6, G-CSF, CXCL1, and other known tu-
mor-promoting inflammatory factors showed strong positive
correlation with those of PTGS2 in samples from human cuta-
neous melanoma (Figures 7A and 7C). No correlation was
observed between PTGS2 levels and levels of markers indicative
of total leukocyte (CD45), regulatory T cell (FOXP3), or B cell
(CD19 and CD20) presence (Figure 7B). In contrast, PTGS2
mRNA levels were inversely correlated with CD8A and CD8B
transcript levels, a measure of the presence of CD8+ T cells in tu-
mors associated with longer survival and favorable treatment
outcome (Fridman et al., 2012; Gajewski et al., 2010). Similarly,
expression of PTGS2 was inversely correlated with that of
CXCL10 and CXCL9, chemokines associated with cytotoxic
T cell recruitment (Fridman et al., 2012; Gajewski et al., 2010)
(Figures 7A and 7D). We also found a significant and consistent
negative association between PTGS2 expression and that of
numerous ISGs (Figures 7A and 7E). Together, these data indi-
cate a qualitative change in immune infiltrate composition that
is driven by COX expression and shows remarkable parallels be-
tween mice and human.
DISCUSSION
The extent to which the immune system acts as a natural barrier
to tumor progression has been the subject of long-standing
debate (Hanahan and Weinberg, 2011). Data from both mouse
and human cancers over the last two decades has lent sup-
port to the notion that neoplastic development is associated
with an immunoediting process, whereby the immune system
selects the outgrowth of less immunogenic tumor cells (Rooney
et al., 2015; Schreiber et al., 2011; Vesely et al., 2011). The
mechanisms underlying immunoediting are only beginning to
be explored and include selection for tumor cells that lose domi-
nant tumor rejection antigens (DuPage et al., 2012; Matsushita
et al., 2012). Here, we uncover PGE2-dependent suppression
of myeloid cell activation as a potent additional mechanism of
tumor immune escape. Our findings suggest that immunoediting
can result in selection of tumors producing immunosuppressive
factors, which block initial type I IFN-dependent innate immune
cell activation and/or prevent subsequent T cell activity against
tumor antigens. The latter indicates that edited tumor cells may
continue to express relevant target antigens that can be func-
tionally unmasked upon removal of tumor-derived suppressive
factors that subvert myeloid cell, including DC, function. These
findings have obvious therapeutic implications, as discussed
below. In addition, they help to explain apparently contradictory
earlier findings suggesting that genetically drivenmouse cancers
are not subject to immune surveillance (Willimsky and Blanken-
stein, 2005) by showing that production of suppressive factors
by the tumor is in fact a feature of immunoediting. The low immu-
nogenicity of tumors can therefore result from immune sculpting
of their antigenic and/or immunostimulatory properties.
Our experiments rely partly on the ability to genetically engi-
neer cancer cells using CRISPR/Cas9-mediated technology to
assess the contribution of specific tumor pathways to immuneell 162, 1257–1270, September 10, 2015 ª2015 The Authors 1263
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Figure 4. Genetic Ablation of COX in BrafV600E or NrasG12D Melanoma Cells Enables Immune-Dependent Tumor Eradication
(A–C) Growth of tumors formed following implantation of 105 control or Ptgs1/Ptgs2/BrafV600E cells intoWT C57BL/6 (A–C),Rag1/ (A), Batf3/, Tap1/ (B),
or Ifnar1/ (C) mice.
(D) Growth of parental BrafV600E cells following implantation into naive WT C57BL/6 mice or mice that previously rejected Ptgs1/Ptgs2/ BrafV600E tumors (pre-
inoculated). Data are compiled from three independent experiments and presented as tumor growth profile (left) and as percentage of tumor-free mice at 6 weeks
post-parental tumor inoculation (right).
(E) Concentration of PGE2 in CM from confluent parental or Pges
/ cell cultures cells or of TNF and IL-6 in the supernatant of an overnight culture of BMMCs
cultured as in Figure 1 in presence of CM from the indicated cell line and expressed as in Figure 1G.
(F) Growth profile of tumors formed following implantation of 105 parental or Pges/ BrafV600E cells into WT or Rag1/ mice.
(G) Concentration of PGE2 in CM from confluent cell cultures or growth profile of tumors formed following implantation of 10
5 parental or Ptgs2/ NrasG12D cells
into WT or Rag1/ mice (right). (H) The percentage of tumor-free mice at 6 weeks post-implantation of parental NrasG12D cells into naive WT C57BL/6 mice or
(legend continued on next page)
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Figure 5. COX Ablation in Colorectal or
Breast Cancer Cells Promotes Cancer-In-
hibiting Inflammation and T-Cell-Dependent
Tumor Growth Control
(A) Concentration of PGE2 in CM from confluent
parental and COX-deficient CT26 and 4T1 cell
cultures cells and of TNF and IL-6 in the superna-
tant of an overnight culture of BMMCs cultured as
in Figure 1 in presence of the indicated cell line CM.
(B) Growth profile of tumors formed following im-
plantation of 105 parental or Ptgs2/ CT26 colo-
rectal or of parental or Ptgs1/Ptgs2/ 4T1 breast
cancer cells into WT Balb/c or nudemice. Data are
presented as average tumor diameters ± SEM and
are representative of at least three independent
experiments with four to sixmice per group. Tumor
growth profiles were compared using two-way
ANOVA. ***p < 0.001.
(C) WT Balb/c mice were inoculated with 106
parental, Ptgs2/ CT26 or Ptgs1/Ptgs2/ 4T1
cells, and 4 days later the expression of an array of
immune-associated genes was determined by
qPCR in whole-tumor homogenates. Heatmaps
for a selected list of genes show log2 DCT values
normalized to hprt of two biological replicates for
each value. The genes are ordered from highest to
lowest by fold change in parental relative to
Ptgs2/ or Ptgs1/Ptgs2/ samples.escape in the absence of alterations in the same pathways in
host stroma. Off-target Cas9 nuclease activity can be a
concern (e.g., Frock et al., 2015), but because we have used
multiple sgRNAs to ablate Ptges1, Ptges2, and/or Pges1/2 in
four different cancer cell lines that, in all cases, become sus-
ceptible to immune-mediated control, we believe that on-target
ablation of the ability of the tumor cells to produce PGE2 ac-
counts for our findings. Similarly, although the introduction of
nucleotide insertions and/or deletions is inherent to the CRISPRmice that previously rejected Ptgs2/ NrasG12D tumors (pre-inoculated). All growth profiles are presented a
sentative of at least two independent experiments with four to six mice per group. Tumor growth profiles we
centage of tumor-free mice using Fisher’s exact test. ***p < 0.001.
See also Figure S6.
Cell 162, 1257–1270, Sepengineering process, it is extremely
improbable that they would in all cases
inadvertently lead to the generation of
neo-self determinants that can be effi-
ciently processed and presented on
H-2 MHC class I molecules for recogni-
tion by CD8+ T cells. We therefore
believe that the antigen targets of CD8+
T cells in COX-deficient tumors are
cancer-associated antigens, mutated
proteins, and/or minor histocompatibility
antigens that are shared with the
parental tumor as denoted by the fact
that immunity to the latter develops in
mice that reject the former. This finding,
in turn, argues against the possibilitythat tumor-derived prostanoids promote immune evasion
merely by preventing tumor infiltration by lymphocytes or ac-
cess of the latter to their targets (Joyce and Fearon, 2015). In
such a scenario, COX-competent parental cells should create
an immune-privileged site and form progressive tumors even
when the host has previously rejected COX-deficient cells.
Antigen-presenting cells, in particular DCs, are greatly
affected by tumor-derived PGE2 and likely to be an important
target of the lipid for tumor immune escape. While DCs haves average tumor diameters ± SEM and are repre-
re compared using two-way ANOVA and the per-
tember 10, 2015 ª2015 The Authors 1265
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Figure 6. COX Inhibition Synergizes with
Anti-PD-1 Blockade in Immune-Dependent
Tumor Growth Control
(A) Left: growth of parental COX-competent tu-
mors following implantation of 105 BrafV600E mel-
anoma cells into C57BL/6 mice. Mice received
aspirin in the drinking water and/or 200 mg of anti-
PD-1 monoclonal antibody i.p. every 3–4 days
from day 3 to day 24. Right: the percentage of mice
that fully rejected tumors over time is shown.
(B) Pooled tumor diameters at 19 days post-im-
plantation of BrafV600E melanoma cells into WT or
Rag1/ mice treated as in (A). Each dot repre-
sents one independent tumor.
(C) As in (A) but using an inoculum of 106 mela-
noma cells.
(D) The percentage of tumor-free mice at 6 weeks
post-implantation of parental BrafV600E cells into
C57BL/6 mice that were untreated (n = 15) (naive)
or that previously rejected BrafV600E cells following
anti-PD-1 (n = 6) or aspirin + anti-PD-1 treatment
(n = 8) (pre-treatment).
(E) As in (A) but C57BL/6 mice received celecoxib
i.p. daily from day 0.
(F) As in (A) but Balb/c mice received 105 CT26
colorectal cells. Growth profiles are presented as
average tumor diameters ± SEM and are repre-
sentative of at least two independent experiments
with five mice per group.
Samples were compared using two-way ANOVA
(A, C, E, and F), one-way ANOVA (B), Fisher’s
exact test (D), and log rank test (A and F). *p < 0.05,
**p < 0.01, ***p < 0.001.been most prominently studied for their ability to prime anti-tu-
mor T cells in lymph nodes, they are also emerging as key players
at the tumor site. Recent studies have indicated that tumor accu-
mulation of rare Batf3-dependent DCs bearing the CD103
marker is associated with good prognosis and immune-medi-
ated control across mouse and human species (Broz et al.,
2014; Ruffell et al., 2014). Batf3-dependent DCs appear to act
by restimulating cytotoxic T lymphocyte (CTL) at the tumor
site, in part by locally providing IL-12. Their dual activity in
cross-priming anti-tumor CTL within lymph nodes and restimu-
lating CTL within tumors probably contributes to the general1266 Cell 162, 1257–1270, September 10, 2015 ª2015 The AuthorsBatf3-dependence of anti-tumor immu-
nity that has been observed in mice (Dia-
mond et al., 2011; Fuertes et al., 2011;
Hildner et al., 2008) and to the suppres-
sion of anti-tumor immunity by PGE2
that we observe here. However, it is likely
that PGE2 acts on additional cell types,
including CTLs themselves. Indeed, CTL
survival and function has been recently
shown to be directly impaired by PGE2
in the context of chronic viral infection
(Chen et al., 2015). Furthermore, we find
that COX activity prevents activation of
the type I IFN system in the tumor micro-
environment, in agreement with recentreports demonstrating an inhibitory role for PGE2 on type I IFN
production during infection with influenza or mycobacteria (Cou-
lombe et al., 2014; Mayer-Barber et al., 2014). This may be espe-
cially relevant to melanoma where the expression of a type I IFN
signature associates with spontaneous remissions (Wenzel
et al., 2005) and increased relapse-free survival (Bald et al.,
2014). Finally, tumor-derived prostanoids directly induce the
production by myeloid cells of known cancer-promoting factors
such as IL-6, CXCL1, and G-CSF, effectively shifting the tumor
microenvironment from one favorable to tumor eradication to
one that has pro-tumor activity.
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Figure 7. COX-2 Levels inHumanMelanoma
Biopsies Correlate Positively with Tumor-
Promoting Factors and Negatively with Fac-
tors Associated with CTL Infiltration and
Type I IFN Signaling
(A–E) Microarray expression data (Talantov et al.,
2005) from human cutaneous melanoma biopsies
containing tumor cells, stroma, and infiltrate were
analyzed for the association of PTGS2 expression
with that of several immune-related genes.
(A) Heatmap for a selected list of genes showing
log2 expression signal for 20% of samples with
highest (high COX-2) and lowest (low COX-2)
PTGS2 expression. Genes were clustered using a
Euclidean distance matrix and average linkage
clustering. Red indicates higher expression, and
blue indicates low expression relative to the mean
expression of the gene across all samples.
(B) Correlation data for PTGS2 versus CD45
(PTPRC), FOXP3, CD19, and CD20 expression.
(C) Correlation data for PTGS2 versus IL-6, G-CSF
(CSF3), CXCL1, and IL-8 expression.
(D) Correlation data for PTGS2 versus CD8A,
CD8B, CXCL10, and CXCL9.
(E) Correlation data for PTGS2 versus the following
ISGs: IFIT1, IFIT2, RIG-I (DDX58), MDA5 (IFIH1),
OAS2, DDX60, ISG15, and IFI16.
In (B)–(E), all cutaneous melanoma samples (n =
45) from the dataset (Talantov et al., 2005) were
included in the analysis, with each dot representing
one sample. The statistical significance of the
correlation was determined using the Pearson’s
correlation coefficient. A linear regression-fitting
curve is shown as a dotted red line.Interestingly, COX-2 is often overexpressed in several human
cancers, including colorectal, breast, stomach, lung, and pan-
creatic tumors (Dannenberg and Subbaramaiah, 2003). Whether
melanomas similarly express abnormal levels of COX-2 remainsCell 162, 1257–1270, Sepunclear (Becker et al., 2009; Denkert
et al., 2001; Goulet et al., 2003; Kuzbicki
et al., 2006). Our analysis of a publically
available dataset of a cohort of human
melanoma biopsies (Talantov et al.,
2005) suggests that the natural variability
in COX-2 expression levels within sam-
ples might be of functional relevance.
Thus, samples with high COX-2 levels
showed higher expression of numerous
tumor-promoting factors, including those
whose expression was directly controlled
by COX in the mouse model. Likewise,
COX-2low melanomas showed a qualita-
tive change in infiltrate composition,
displaying increased expression of anti-
tumor mediators and hallmarks of activa-
tion of the type I IFN system. Thus, our
combined analysis of the mouse model
and the human samples argues for COX
activity as a common mechanism co-opted by cancer cells to promote immune escape across
species.
Prostanoids have been implicated in carcinogenesis through
enhancement of cancer cell survival, proliferation, invasion,tember 10, 2015 ª2015 The Authors 1267
and angiogenesis (Wang and Dubois, 2010). COX inhibitors were
recently reported to enhance the efficacy of antiangiogenic
therapy in pre-clinical models by inhibiting VEGF-independent
PGE2-induced tumor angiogenesis (Xu et al., 2014). As such, it
is remarkable that COX-deficient cancer cells are able to grow
indistinguishably from their COX-competent counterparts in
immunodeficient mice. These results indicate that, at least for
some tumors, the main role of cancer-cell-derived prostanoid
production is to promote immune evasion and that any effects
on angiogenesis or tumor cell survival and proliferation are likely
secondary to immune suppression or redundant with stroma-
derived PGE2. Notably, our findings that COX-2 expression
depends on active RAF/MEK signaling suggests that reduced
production of PGE2 by melanoma cells may contribute to the im-
mune-dependent anti-cancer activity elicited by BRAF inhibitors
(Frederick et al., 2013; Knight et al., 2013). Nevertheless, COX-2
upregulation is likely to also be driven by MAPK-independent
pathways, consistent with the presence of multiple regulatory el-
ements in the PTGS2 promoter.
We find a remarkable conservation between signatures of
COX-dependent subversion of inflammation across mouse and
human melanoma. We therefore propose that COX-2 levels
and COX-dependent inflammatory mediators in human mela-
noma and other cancers might constitute useful biomarkers
predictive of prognosis and treatment outcome, including in
response to checkpoint blockade inhibitors, such as anti-
CTLA4 and anti-PD-1/PD-L1. Finally, our data show that COX in-
hibitors act synergistically with anti-PD-1 mAb in pre-clinical
models. We therefore speculate that COX inhibitors, reported
to reduce the risk of several cancers, including colorectal (Roth-
well et al., 2010), gastric (Tian et al., 2010), breast cancer (Gier-
ach et al., 2008), and, even, melanoma (Gamba et al., 2013),
might help unleash anti-cancer immunity and thereby constitute
useful additions to the arsenal of conventional and immune-
based cancer therapies, most notably those based on immune
checkpoint blockade.
EXPERIMENTAL PROCEDURES
Mice
All animal experiments were performed in accordance with national and insti-
tutional guidelines for animal care and were approved by an institutional Ani-
mal Ethics Committee and by the Home Office, UK.
Cancer Cell Lines
Cells were cultured under standard conditions and were confirmed to be my-
coplasma free. BrafV600E and NrasG12D melanoma cell lines were established
from C57BL/6 Braf+/LSL-V600E;Tyr::CreERT2+/o;p16INK4a/ (Dhomen et al.,
2009) and C57BL/6 Nras+/LSL-G12D;Tyr::CreERT2+/o (Pedersen et al., 2013)
mice, respectively. CT26, 4T1, and EL4 cells were from ATCC. Ptgs2/,
Ptgs1/Ptgs2/, and Pges/ cells were generated by CRISPR/Cas9-medi-
ated genome engineering using the CRISPR design tool provided by the Zhang
lab (http://www.genome-engineering.org). Correctly targeted clones were
selected based on their inability to produce PGE2, and genetic ablation of
COX-1, COX-2, mPGES-1, and mPGES-2 was verified by sequencing.
Tumor Cell Injections
Tumor cells were harvested by trypsinization, washed three times with PBS,
and injected subcutaneously into the right flank of recipient mice at 105 to
106 cells in 100 ml of endotoxin-free PBS. Tumor cells were >98% viable at
the time of injection as determined by propidium iodide staining. Tumor size1268 Cell 162, 1257–1270, September 10, 2015 ª2015 The Authorswas quantified as the mean of the longest diameter and its perpendicular.
For COX inhibition in vivo, aspirin was administered in the drinking water at
600 mg/ml 1 to 3 days before injection of tumor cells and replaced every
3 days. Alternatively, mice received 200 ml of celecoxib (Sigma and LC Labo-
ratories) intraperitoneally (i.p.) at 500 mg/ml (12.5% DMSO in PBS) daily from
day 0. Anti-PD-1 monoclonal antibody (clone RMP1-14, BioXCell) was admin-
istered i.p. at 200 mg/mouse from day 3 post-tumor cell inoculation every 3 to
4 days for a maximum of six injections.
In Vitro Culture
Mouse BMMCs were generated using GM-CSF as described (Helft et al.,
2015). Cells were plated at 0.5- to 1 3 106 cells/ml in 96-well plates at 37C
in absence or presence of 100 ml of conditioned medium from tumor cells
plus or minus LPS (10 to 100 ng/ml) in a total volume of 200 ml. After overnight
culture, cytokine and chemokine concentration in the supernatant was deter-
mined by ELISA or by cytometric bead array using standard procedures.
qPCR
Tumors were collected and homogenized, and total RNA was isolated with Tri-
zol reagent (Invitrogen) and further purified on RNAeasy columns (QIAGEN).
cDNA was synthesized using SuperscriptII reverse transcriptase (Invitrogen).
Expression of an array of immune genes was performed using a TaqMan
mouse immune array (v.2.1), following the manufacturer’s instructions.
Human Microarray Dataset Analysis
Raw CEL files from the microarray dataset GSE3189 were downloaded from
GEO (http://www.ncbi.nlm.nih.gov).
Statistics
Statistical significancewas determined using an unpaired two-tailed Student’s
t test, one-way ANOVA, two-way ANOVA, Fisher’s exact test, log rank test,
and the Pearson correlation coefficient as indicated. A p value < 0.05 was
considered significant (* p < 0.05; ** p < 0.01; *** p < 0.001).
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